Today, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by BioNTech and Pfizer, making it the first COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.

The President of the European Commission, Ursula von der Leyen, said: “Today we add an important chapter to a European success story. We approved the first safe and effective vaccine against COVID-19. More vaccines will come soon. Doses of the vaccine approved today will be available for all EU countries, at the same time, on the same conditions. The upcoming European vaccination days will also be a great moment of unity. This is a good way to end this difficult year, and to start turning the page on this pandemic. We are all in this together.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: This is a big day for Europe. It is a day of true European solidarity in action. After  months of  work, we are seeing our EU Vaccines Strategy bear fruit – access to safe, effective and affordable vaccines at the same time for all Member States. Today we witness what can be achieved collectively when we work together in a strong European Health Union. A Europe that cares and that supports. A Europe that leaves no stone unturned.”

BioNTech and Pfizer made a formal application for a conditional marketing authorisation on 1 December. This followed the analysis of their data in a ‘rolling review’ by EMA as from 6 October. Thanks to this rolling review, EMA managed to assess the conditional marketing authorisation application very rapidly. This procedure, specifically designed for emergency situations, ensures as swift an assessment as possible while ensuring that all requirements in terms of safety, effectiveness and quality of the vaccine are fully and thoroughly evaluated.

On the basis of EMA’s positive opinion, the Commission has verified all the elements supporting the marketing authorisation and consulted Member States before granting the conditional market authorisation.

The BioNTech/Pfizer vaccine is based on messenger RNA (mRNA) technology. This allows cells to manufacture harmless fragments of viral proteins that the human body uses to build an immune response to prevent or fight subsequent, natural infection. When a person is given the vaccine, their cells will read the genetic instructions and produce fragments of the ‘spike protein’, a protein on the outer surface of the virus which it uses to enter the body’s cells, to replicate, and cause disease. The person’s immune system will then treat this protein as foreign and produce natural defences — antibodies and T cells — against it.

Read more at:


Comments are closed

Acerca de este sitio

La ACIEAU es una plataforma de networking profesional de científicos e investigadores españoles que trabajan en los Emiratos Árabes Unidos. Cuenta con más de 60 miembros, incluidos destacados científicos, investigadores y expertos en una amplia gama de áreas de conocimiento: desde Ingeniería, Medio Ambiente, Salud, Veterinaria y Biología, hasta Ciencias Sociales e Inteligencia Artificial. Su propósito es difundir los logros científicos y tecnológicos de los investigadores españoles en los Emiratos Árabes Unidos.